Exhibit 99.1

|                                                                                                                              |               
|----------------------------------------------------------------------------------------------------------------------------- | --------------
|Angeion
 Corporation 
 350 Oak Grove Parkway 
 St. Paul, MN 55127 USA 
 Telephone: (651) 484-4874 
 Facsimile: (651) 484-4826 | (ANGEION LOGO)

FOR IMMEDIATE RELEASE

Angeion Corporation Names Scott Shuda to Board of
Directors

SAINT PAUL, Minn. (March 9, 2010)
Angeion Corporation (NASDAQ: ANGN) today announced that Scott Shuda has been
named to the companys board of directors.

Shuda is the
Managing Director and Co-founder of Danville, Calif.-based BlueLine Partners, a
special situations investment firm that focuses on publicly listed technology
and healthcare companies. He brings more than a decade of professional
experience in law, technology and entrepreneurial endeavors, as well as
transaction experience that ranges from initial public offerings and venture
financings to mergers and acquisitions.

We are
excited to welcome Scott to our board, said Rodney A. Young, President and
Chief Executive Officer of Angeion. Scott brings a wealth of financial and
legal experience and a proven track record of successhell be a tremendous
asset for Angeion as we expand our presence in health optimization.

Prior to
co-founding BlueLine Partners, Shuda was employed as an attorney in New York
City and Silicon Valley. Positions held include serving as General Counsel to
Vicinity Corporation, an internet company that went public in 2000 and was
acquired by Microsoft in 2002. Shuda has a law degree and a master of business
administration degree from the Georgetown University.

Regarding his
appointment, Shuda said, I am very pleased to join Angeion at such a pivotal
point in the companys evolution. I believe that Angeion possesses significant
potential and I look forward to working with management and the other
shareholders on strategies that will reward shareholders for their support of
the company.

1

---



About Angeion Corporation

Founded in
1986, Angeion Corporation acquired Medical Graphics Corporation in December
1999. Medical Graphics develops, manufactures and markets non-invasive
cardiorespiratory diagnostic systems that are sold under the MedGraphics (www.medgraphics.com)
and New Leaf (www.newleaffitness.com) brand and trade names. These
cardiorespiratory diagnostic systems have a wide range of applications in
healthcare as well as health and fitness. The Companys products are sold
internationally through distributors and in the United States through a direct
sales force that targets heart and lung specialists located in hospitals, university-based
medical centers, medical clinics and physicians offices, pharmaceutical
companies, medical device manufacturers, clinical research organizations,
health and fitness clubs, personal training studios, and other exercise
facilities. For more information about Angeion, visit www.angeion.com.

|         |                                                                                                                                            
|-------- | -------------------------------------------------------------------------------------------------------------------------------------------
|Contact: | Rodney A.
 Young, President and Chief Executive Officer, (651) 484-4874 William J.
 Kullback, SVP & Chief Financial Officer, (651) 766-3492

Forward Looking Statements

The discussion above
contains forward-looking statements about Angeions future financial results
and business prospects that by their nature involve substantial risks and
uncertainties. You can identify these statements by the use of words such as
anticipate, believe, estimate, expect, project, intend, plan,
will, target, and other words and terms of similar meaning in connection
with any discussion of future operating or financial performance or business
plans or prospects. Our actual results may differ materially depending on a
variety of factors including: (1) national and worldwide economic and capital
market conditions; (2) continuing cost-containment efforts in our hospital,
clinics, and office market; (3) any changes in the patterns of medical
reimbursement that may result from national healthcare reform; (4) our ability
to successfully operate our business, including successfully converting our
increasing research and development expenditures into new and improved
cardiorespiratory diagnostic products and services and selling these products
and services under the MedGraphics and New Leaf brand names into existing and
new markets; (5) our ability to maintain our cost structure at a level that is
appropriate to our near to mid-term revenue expectations and that will enable
us to increase revenues and profitability as opportunities develop (6) our
ability to achieve constant margins for our products and consistent and
predictable operating expenses in light of variable revenues from our clinical
research customers; (7) our ability to expand our international revenue through
our distribution partners and our Milan, Italy representative branch office;
(8) our ability to successfully defend ourselves from product liability claims
related to our cardiorespiratory diagnostic products and claims associated with
our prior cardiac stimulation products; (9) our ability to defend our
intellectual property; (10) our ability to develop and maintain an effective
system of internal controls and procedures and disclosure controls and
procedures; and (11) our dependence on third-party vendors. Additional information
with respect to the risks and uncertainties faced by the Company may be found
in, and the above discussion is qualified in its entirety by, the other risk
factors that are described from time to time in the Companys Securities and
Exchange Commission reports, including the Annual Report on Form 10-K for the
year ended October 31, 2009.

###

2

---